{"document_type": "article", "snippet": "Valeant, which has grown by acquiring rivals and slashing their staffs, has drawn the ire of a House panel, which is now considering a subpoena on the company\u2019s price increases.", "type_of_material": "News", "web_url": "http://www.nytimes.com/2015/10/04/business/valeants-high-price-drug-strategy.html", "subsection_name": null, "blog": [], "section_name": "Business Day", "source": "The New York Times", "pub_date": "2015-10-04T00:00:00Z", "word_count": "1070", "slideshow_credits": null, "news_desk": "SundayBusiness", "byline": {"original": "By GRETCHEN MORGENSON", "person": [{"role": "reported", "lastname": "MORGENSON", "rank": 1, "organization": "", "firstname": "Gretchen"}]}, "abstract": "Gretchen Morgenson Fair Game column observes that investors in drug companies are starting to see the danger in firms like Valeant Pharmaceuticals raising prices indiscriminately to increase stock prices; points out House panel may issue subpoena against Valeant. ", "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "rank": "1", "name": "organizations", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "rank": "2", "name": "subject", "is_major": "Y"}, {"value": "Stocks and Bonds", "rank": "3", "name": "subject", "is_major": "N"}, {"value": "Prices (Fares, Fees and Rates)", "rank": "4", "name": "subject", "is_major": "N"}, {"value": "Cummings, Elijah", "rank": "5", "name": "persons", "is_major": "N"}, {"value": "House Committee on Oversight and Government Reform", "rank": "6", "name": "organizations", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "rank": "7", "name": "subject", "is_major": "N"}, {"value": "Corporate Taxes", "rank": "8", "name": "subject", "is_major": "N"}, {"value": "Pearson, John Michael (1959- )", "rank": "9", "name": "persons", "is_major": "N"}], "print_page": "1", "multimedia": [{"subtype": "wide", "legacy": {"wideheight": "126", "wide": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbWide.jpg", "widewidth": "190"}, "type": "image", "width": 190, "height": 126, "url": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbWide.jpg"}, {"subtype": "xlarge", "legacy": {"xlargeheight": "413", "xlargewidth": "600", "xlarge": "images/2015/10/04/business/04gret-web1/04gret-web1-articleLarge.jpg"}, "type": "image", "width": 600, "height": 413, "url": "images/2015/10/04/business/04gret-web1/04gret-web1-articleLarge.jpg"}, {"subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "type": "image", "width": 75, "height": 75, "url": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbStandard.jpg"}], "lead_paragraph": "Valeant, which has grown by acquiring rivals and slashing their staffs, has drawn the ire of a House panel, which is now considering a subpoena on the company\u2019s price increases.", "headline": {"kicker": "Fair Game", "content_kicker": "Fair Game", "print_headline": "Side Effects of Hijacking Drug Prices", "main": "Valeant\u2019s High-Price Drug Strategy"}, "_id": "560ea61638f0d81aa77a547d"}